List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Identifying Drugs to Treat Age-Dependent Neurodegeneration

    SBC: EXPRESSION DRUG DESIGN LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Defining the molecular mechanism that leads to cellular aging and neural degeneration has proven to be difficult. Many types of damage are thought to contribute to senescence and neural degeneration and include mitochondrial and nuclear DNA mutations, protein misfolding, aggregate formation, reactive oxygen species (ROS), and stem cell senescence. However, a co ...

    SBIR Phase II 2011 Department of Health and Human Services
  2. Bacterial-Induced Sepsis: A New Treatment Strategy

    SBC: TARGETED GENE DELIVERY, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Sepsis is a prevalent and life-threatening medical condition characterized by development of a dysregulated inflammatory immune response and associated tissue damage. This dysregulated inflammatory response is initiatedby activation of Toll-Like receptor (TLR) signaling in response to bacteria and/or bacterial products, such as LPS. Current treatments are limit ...

    SBIR Phase II 2011 Department of Health and Human Services
  3. A Monoclonal Antibody Immunoprotectant for Ebola Virus

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The National Institutes of Health considers the development of therapeutics against potential bioterrorism agents a national research priority. There is a particular need for immunotherapeutics against Ebola virus (a Category A agent). Because of Ebola's lethality and reports that it has been weaponized, public health officials and defense agencies have mo ...

    SBIR Phase II 2011 Department of Health and Human Services
  4. Chemical Stabilization of shRNAs and their development as hepatitis C drugs

    SBC: Somagenics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a worldwide health problem, and its treatment and prevention remain a major challenge. Existing therapies are only partially effective and have serious side effects. No vaccine is currently available. RNA interference (RNAi) offers a novel therapeutic approach for treating HCV infections. We have identified a class of shRNAs, called s ...

    SBIR Phase II 2011 Department of Health and Human Services
  5. Development of a Yellow Fever Vaccine for Vulnerable Population

    SBC: NAJIT TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Yellow fever virus (YFV) was at one time endemic in the United States and represents a mosquito-borne emerging/re-emerging human pathogen that causes up to 20% mortality. The current live attenuated YFV vaccine was developed in 1936 and following the development of a virus seed lot system, it has not been modified or otherwise improved in over 50 years. Accordi ...

    SBIR Phase II 2011 Department of Health and Human Services
  6. A Cell-based Assay for Botulinum Neurotoxin Detection and Development

    SBC: BIOSENTINEL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most toxic substances known to humans, causing respiratory failure. Because of their lethality and ease of production, the Department of Defense (DoD) designates BoNTs as a categoryA bioterrorism agent. Developing effective, post-exposure antagonists to BoNT is among DoD's top priorities. Despite their lethality, BoNT ...

    SBIR Phase II 2011 Department of Health and Human Services
  7. Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis

    SBC: AURITEC PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Large efforts are currently underway funded by the NIH, the Gates foundation, and the WHO, to reduce the spread of HIV transmission by developing an effective microbicide. The CAPRISA trial with tenofovir gel is the first demonstration of prophylaxis against HIV and HSV using a topical microbicide. Because protection increased with increasing adherence, and bec ...

    SBIR Phase II 2011 Department of Health and Human Services
  8. Interactive Program to Manage and Prevent Back Pain

    SBC: Oregon Center For Applied Science, Inc            Topic: NIAMS

    DESCRIPTION (provided by applicant): At some point in their lives, 80 percent of the work force will suffer some form of back pain. It is the leading cause of work-related disability in the U.S., costing billions of dollars in lost productivity and high medical, insurance, and legal costs. For workers suffering from nonspecific low back pain (NLBP) that does not require medical attention, the Amer ...

    SBIR Phase II 2011 Department of Health and Human Services
  9. Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs

    SBC: TRANSDERM, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and selective, demonstrating remarkable single-nucleotide specificity.Clinical trials using siRNAs are currently underway for a number of indications including skin. Facilitated by Phase 1 funding, a small one pati ...

    SBIR Phase II 2011 Department of Health and Human Services
  10. Exploiting synthetic lethality of hematopoietic lineage cells to develop novel ta

    SBC: Cellecta, Incorporated            Topic: NCI

    DESCRIPTION (provided by applicant): Targeted therapies have the ability to specifically interact with and block proliferation of cancer cells by interfering with targeted gene products required for the malignant phenotype. Unlike conventional cancer chemotherapies, targeted therapies do not harm normal cells of the body. This class of therapeutic has been met with considerable clinical success i ...

    SBIR Phase II 2011 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government